Breast CancerNCT02606708
Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy
A study testing Accelerated intensity modulated radiation therapy (AIMRT) in people with Breast Cancer, run by NYU Langone Health at 1 site in United States.
Trial summary
The primary purpose of this study is to determine the feasibility and tolerability of a regimen of accelerated (hypofractionated) Intensity Modulated Radiation Therapy (AIMRT) to the whole breast as part of breast preservation. Read more about this study
- Who is it for?
- Ages 19 to 90 years, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- Accelerated intensity modulated radiation therapy (AIMRT)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 314 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Feb 2005to 2 Jun 2017
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 90 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Pre- or post-menopausal women with Stage I and II breast cancer
- Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm
- Status post segmental mastectomy. and after sentinel node biopsy and/or axillary node dissection
- At least 2 weeks from last chemotherapy
- Tumors < 5 mm do not require nodal assessment
Who cannot join
- Previous radiation therapy to the ipsilateral breast.
- More than 3 involved nodes identified at axillary staging, requiring adjuvant axillary radiation.
- Active connective tissue disorders, such as lupus or scleroderma.
- Prior or concurrent malignancy other than basal or squamous cell skin cancer or carcinoma in-situ of the cervix, unless disease-free > 5 years.
- Pregnant or lactating women.
Trial locations and contacts
1 site in 1 country.
United States1 site
NYU Langone Medical Center
New York, New York, 10003
About this study
Official title: Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy: a Pilot Study
The primary purpose of this study is to determine the feasibility and tolerability of a regimen of accelerated (hypofractionated) Intensity Modulated Radiation Therapy (AIMRT) to the whole breast as part of breast preservation. In addition, the investigators want to prospectively collect blood specimens to: assess TGF-β polymorphisms to identify potential carriers at higher risk for post-treatment fibrosis; generate a blood specimen repository for future studies of other relevant polymorphisms. The study investigators also want to prospectively follow each treated woman yearly to assess long-term radiation sequelae of the current regimen by using the LENT/SOMA scores.
Read the detailed description
Despite level I evidence of comparable efficacy to that of mastectomy, breast conserving therapy (BCT) remains underutilized in the United States. In 1990, the National Institutes of Health (NIH) Consensus Development Conference concluded that BCT was the appropriate method of treatment for the majority of women with early stage I and II breast cancer. However, this subsequently only translated in a moderate increase in the utilization of BCT, shifting from 34% to 60% for stage I breast cancer and from 19% to 39% for stage II breast cancer.
There appear to be multiple causes for underutilization. The demands of the standard radiation schedule probably play the main role. Generally, post-lumpectomy radiation therapy consists of 4 to 5 weeks of whole breast radiation of a total dose 45 to 50 Gy in 23-25 fractions, usually followed by a boost of 10 to 16 Gy in 5-8 fractions to the tumor bed area. The total length of treatment is 5-7 weeks, commonly six weeks. Practically, women who choose BCT automatically commit to a regimen of approximately six weeks of daily radiation visits (Monday to Friday) to complete the local management of their breast cancer. For many women, concerns about this commitment are likely to influence the choice for mastectomy instead of breast preservation since only 40-60% of women who meet criteria for BCT actually undergo the procedure. In addition to possible biases of the primary health care provider affecting these choices, it is known that distance from RT treatment facilities also plays an important role in women's choice for mastectomy instead of BCT. Unfortunately, 15-30% of patients who have actually selected BCT, in particularly older patients and those with 2 or more co-morbid conditions, do not receive postoperative RT. These facts warrant a critical assessment of standard radiation therapy in this clinical setting.
The actual standard approach to post-segmental mastectomy adjuvant radiation at our institution consists of surgical excision followed by 6 weeks of breast irradiation for a total of 30 fractions of 2 Gy each, 23 (46 Gy) to the whole breast while 7 to the original tumor bed (14 Gy). Instead, the women in this study will only receive 15 larger radiation fractions (2.7 Gy) to the entire breast with a concomitant boost to the tumor bed (2.7 Gy + .5 Gy, total 3.2 Gy per fraction). All women will be treated prone to best apply IMRT techniques while avoiding the rest of the body.
Treatment with fewer fractions over a shorter duration of time offers several advantages, provided it is as effective as the conventional treatment regimens and without added morbidity. The potential advantages include: 1) less time away from homes, families and jobs; 2) less cost associated with travel and time away from work; 3) ease the demand on radiation treatment resources and produce savings to the health-care system. Moreover, treatment prone assures that only minimal dose of radiation is delivered to the lung, heart and to the controlateral breast.
Patients will have completed all breast surgical procedures prior to accrual into this protocol in order to establish eligibility criteria. All patients will then be treated prone with 2.7 Gy/fraction delivered in 15 fractions over a 3-week period for a total dose of 40.5 Gy.
All patients will be followed 1, 3, 6, 12 months after treatment course, then yearly thereafter.
- Conditions
- Breast Cancer
- Being tested
- Accelerated intensity modulated radiation therapy (AIMRT)
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Accelerated intensity modulated radiation therapy (AIMRT)Radiation
| Study group | Role | What they receive |
|---|---|---|
| Accelerated intensity modulated radiation therapy (AIMRT) | Experimental | All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered. Receives: Radiation: Accelerated intensity modulated radiation therapy (AIMRT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Local Recurrence in Breast
Defined by the discovery of invasive disease or DCIS in the same region of the breast after segmental mastectomy and radiation, by clinical or radiographic means.
Measured: 5 years
Number of Participants With Regional Recurrence
Defined by the discovery of invasive disease or DCIS regional recurrence in the lymph node after segmental mastectomy and radiation, by clinical or radiographic means.
Measured: 5 years
Number of Participants With Contralateral Breast Cancer
Defined by the discovery of contra-lateral breast cancer after segmental mastectomy and radiation, by clinical or radio-graphic means.
Measured: 5 years
Number of Participants With Distant Metastases
number of participants found to have distant metastases after segmental mastectomy and radiation, by clinical or radiographic means
Measured: 5 years
Number of Participants With an Outcome of Death
Overall 5-Year cumulative rate of death based on Kaplan-Meier Analysis
Measured: 5 years
Secondary outcomes (3)
Maximum Grade Late Radiation Toxicity
Measure of treatment related late toxicities at or more than 6 months after completion of radiation therapy.
Measured: 5 years
Patient Self-assessment of the Cosmetic Results
Measured: 5 years
Survival
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Nov 2015 (estimated)
- Study start20 Feb 2005
- Primary completion2 Jun 2016
- Study completion2 Jun 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by NYU Langone HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 314 participants (actual)
Sponsor and investigators
- Lead sponsor
- NYU Langone Health
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Carmen Perez, MD, Principal investigator, NYU Langone Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02606708
- Sponsor's protocol ID
- 11105
- Status last verified
- Jul 2020
- First submitted
- 30 Sep 2015
- Last updated
- 14 Aug 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy: a Pilot Study
- ClinicalTrials.gov ID
- NCT02606708
- Acronym / sponsor ID
- 11105
- Conditions
- Breast Cancer
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 314 participants (actual)
- Lead sponsor
- NYU Langone HealthUniversity, hospital or other
- Study start
- 20 Feb 2005 (actual)
- Primary completion
- 2 Jun 2016 (actual)
- Study completion
- 2 Jun 2017 (actual)
- First posted
- 17 Nov 2015 (estimated)
- Results
- Posted 14 Aug 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary purpose of this study is to determine the feasibility and tolerability of a regimen of accelerated (hypofractionated) Intensity Modulated Radiation Therapy (AIMRT) to the whole breast as part of breast preservation. In addition, the investigators want to prospectively collect blood specimens to: assess TGF-β polymorphisms to identify potential carriers at higher risk for post-treatment fibrosis; generate a blood specimen repository for future studies of other relevant polymorphisms. The study investigators also want to prospectively follow each treated woman yearly to assess long-term radiation sequelae of the current regimen by using the LENT/SOMA scores.
Detailed description
Despite level I evidence of comparable efficacy to that of mastectomy, breast conserving therapy (BCT) remains underutilized in the United States. In 1990, the National Institutes of Health (NIH) Consensus Development Conference concluded that BCT was the appropriate method of treatment for the majority of women with early stage I and II breast cancer. However, this subsequently only translated in a moderate increase in the utilization of BCT, shifting from 34% to 60% for stage I breast cancer and from 19% to 39% for stage II breast cancer.
There appear to be multiple causes for underutilization. The demands of the standard radiation schedule probably play the main role. Generally, post-lumpectomy radiation therapy consists of 4 to 5 weeks of whole breast radiation of a total dose 45 to 50 Gy in 23-25 fractions, usually followed by a boost of 10 to 16 Gy in 5-8 fractions to the tumor bed area. The total length of treatment is 5-7 weeks, commonly six weeks. Practically, women who choose BCT automatically commit to a regimen of approximately six weeks of daily radiation visits (Monday to Friday) to complete the local management of their breast cancer. For many women, concerns about this commitment are likely to influence the choice for mastectomy instead of breast preservation since only 40-60% of women who meet criteria for BCT actually undergo the procedure. In addition to possible biases of the primary health care provider affecting these choices, it is known that distance from RT treatment facilities also plays an important role in women's choice for mastectomy instead of BCT. Unfortunately, 15-30% of patients who have actually selected BCT, in particularly older patients and those with 2 or more co-morbid conditions, do not receive postoperative RT. These facts warrant a critical assessment of standard radiation therapy in this clinical setting.
The actual standard approach to post-segmental mastectomy adjuvant radiation at our institution consists of surgical excision followed by 6 weeks of breast irradiation for a total of 30 fractions of 2 Gy each, 23 (46 Gy) to the whole breast while 7 to the original tumor bed (14 Gy). Instead, the women in this study will only receive 15 larger radiation fractions (2.7 Gy) to the entire breast with a concomitant boost to the tumor bed (2.7 Gy + .5 Gy, total 3.2 Gy per fraction). All women will be treated prone to best apply IMRT techniques while avoiding the rest of the body.
Treatment with fewer fractions over a shorter duration of time offers several advantages, provided it is as effective as the conventional treatment regimens and without added morbidity. The potential advantages include: 1) less time away from homes, families and jobs; 2) less cost associated with travel and time away from work; 3) ease the demand on radiation treatment resources and produce savings to the health-care system. Moreover, treatment prone assures that only minimal dose of radiation is delivered to the lung, heart and to the controlateral breast.
Patients will have completed all breast surgical procedures prior to accrual into this protocol in order to establish eligibility criteria. All patients will then be treated prone with 2.7 Gy/fraction delivered in 15 fractions over a 3-week period for a total dose of 40.5 Gy.
All patients will be followed 1, 3, 6, 12 months after treatment course, then yearly thereafter.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Accelerated intensity modulated radiation therapy (AIMRT) | Experimental | Radiation: Accelerated intensity modulated radiation therapy (AIMRT)All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered. |
Who may qualify
- Ages
- 19 to 90 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Pre- or post-menopausal women with Stage I and II breast cancer
- Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm
- Status post segmental mastectomy. and after sentinel node biopsy and/or axillary node dissection
- At least 2 weeks from last chemotherapy
- Tumors < 5 mm do not require nodal assessment
Key exclusion criteria (5 listed)
- Previous radiation therapy to the ipsilateral breast.
- More than 3 involved nodes identified at axillary staging, requiring adjuvant axillary radiation.
- Active connective tissue disorders, such as lupus or scleroderma.
- Prior or concurrent malignancy other than basal or squamous cell skin cancer or carcinoma in-situ of the cervix, unless disease-free > 5 years.
- Pregnant or lactating women.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Accelerated intensity modulated radiation therapy (AIMRT) | Radiation | Accelerated intensity modulated radiation therapy (AIMRT) |
Primary outcome
Number of Participants With Local Recurrence in Breast
Time frame: 5 years
Defined by the discovery of invasive disease or DCIS in the same region of the breast after segmental mastectomy and radiation, by clinical or radiographic means.
Number of Participants With Regional Recurrence
Time frame: 5 years
Defined by the discovery of invasive disease or DCIS regional recurrence in the lymph node after segmental mastectomy and radiation, by clinical or radiographic means.
Number of Participants With Contralateral Breast Cancer
Time frame: 5 years
Defined by the discovery of contra-lateral breast cancer after segmental mastectomy and radiation, by clinical or radio-graphic means.
Number of Participants With Distant Metastases
Time frame: 5 years
number of participants found to have distant metastases after segmental mastectomy and radiation, by clinical or radiographic means
Number of Participants With an Outcome of Death
Time frame: 5 years
Overall 5-Year cumulative rate of death based on Kaplan-Meier Analysis
3 secondary outcomes
Maximum Grade Late Radiation Toxicity
Time frame: 5 years
Patient Self-assessment of the Cosmetic Results
Time frame: 5 years
Survival
Time frame: 5 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carmen Perez, MD principal investigator
NYU Langone Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Accelerated intensity modulated radiation therapy (AIMRT) in people with Breast Cancer, run by NYU Langone Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 Aug 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Local Recurrence in Breast (time frame: 5 years). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2020.